Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations?
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 1
Abstract
The objective of this article is to compare and contrast the international expectations associated with the model-independent similarity factor approach to comparing dissolution profiles. This comparison highlights globally divergent regulatory requirements to meet local dissolution similarity requirements. In effect, experiments customized to meet the current international regulatory expectations for dissolution and drug release unnecessarily increase manufacturing costs, hinder science and risk-based approaches, increase collective regulatory burden, reduce continuous improvement and innovation, and potentially delay patient access to urgently needed medication. Comparative assessment of regulatory differences in applying dissolution to demonstrate product similarity is crucial to reduce non-scientifically justified experiments and foster collaborative harmonization among global regulatory health authorities and the pharmaceutical industry.
Authors and Affiliations
Dorys Argelia Diaz, Stephen T. Colgan, Connie S. Langer, Nagesh T. Bandi, Michael D. Likar, Leslie Van Alstine
Keywords
Related Articles
- EP ID EP680817
- DOI 10.1208/s12248-015-9830-9
- Views 58
- Downloads 0
Alginate–Chitosan–PLGA Composite Microspheres Enabling Single-Shot Hepatitis B Vaccination
Hepatitis B vaccination typically requires a multi-dose administration protocol over a course of 3–6 months. Aiming at developing a single-shot formulation for hepatitis B vaccine (hepatitis B surface ant...
2005 AAPS Biotechnology Conference Open Forum on Aggregation of Protein Therapeutics — Panel Discussion June 5–8, 2005 San Francisco, CA
2D-Cosy NMR Spectroscopy as a Quantitative Tool in Biological Matrix: Application to Cyclodextrins
Classical analytical quantifications in biological matrices require time-consuming sample pre-treatments and extractions. Nuclear magnetic resonance (NMR) analysis does not require heavy sample treatments or extractions...
CYP2D6 Genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting
The emerging application of pharmacogenomics in the clinical trial setting requires careful comparison with more traditional phenotyping methodologies, particularly in the drug metabolism area where phenotyping is used e...
PTD-mediated Loading of Tumor-Seeking Lymphocytes with Prodrug-Activating Enzymes
Using the approach of peptide transduction domain (PTD)-mediated loading of interleukin-2(IL-2)-activated natural killer (A-NK) cells, tumor-seeking lymphocytes, with prodrug-activating enzymes, we primarily aim to gener...